{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T17:54:25Z","timestamp":1785779665915,"version":"3.56.0"},"reference-count":53,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["DTB"],"abstract":"<jats:p>\n                    Gonorrhoea, caused by the bacterium\n                    <jats:italic>Neisseria gonorrhoeae<\/jats:italic>\n                    , is the second most common bacterial sexually transmitted infection diagnosed in the UK. Diagnoses remain highest among specific population groups: men who have sex with men, young people aged 15\u201324 years, and individuals of black Caribbean and mixed ethnicities. While most infections are asymptomatic, gonococcal infection can cause painful urogenital symptoms and, left untreated, can result in complications including pelvic inflammatory disease, epididymo-orchitis and infertility. Although infections can be treated successfully, there has been a concerning rise in diagnoses of antibiotic-resistant gonorrhoea in recent times. Treatment options are limited due to antimicrobial resistance and a lack of newer treatment options available. Sexual contacts should be treated if they test positive. Ceftriaxone remains a safe, effective first-line treatment. Ceftriaxone-resistant cases are being detected more frequently although numbers remain low in England and Wales. The recent roll-out of the world\u2019s first vaccination programme to protect against gonorrhoea infection is anticipated to save the NHS millions of pounds over the next decade. It remains to be seen whether this measure will effectively curb escalating national infection rates.\n                  <\/jats:p>","DOI":"10.1136\/dtb.2025.000038","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T17:20:25Z","timestamp":1785777625000},"page":"dtb-2025-000038","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Management of urogenital gonococcal infection"],"prefix":"10.1136","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-4558-4036","authenticated-orcid":false,"given":"Soonita","family":"Oomeer","sequence":"first","affiliation":[{"name":"Genitourinary Medicine, Central and North West London NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"2026080310201422000_dtb.2025.000038v1.1","doi-asserted-by":"crossref","unstructured":"Walker CK , Sweet RL . Gonorrhea infection in women: prevalence, effects, screening, and management. Int J Womens Health 2011;197\u2013206. doi:10.2147\/IJWH.S13427","DOI":"10.2147\/IJWH.S13427"},{"key":"2026080310201422000_dtb.2025.000038v1.2","doi-asserted-by":"publisher","DOI":"10.1086\/380838"},{"key":"2026080310201422000_dtb.2025.000038v1.3","doi-asserted-by":"crossref","unstructured":"Unemo M , Ross J , Serwin A , et al . 2020 European guideline for the diagnosis and treatment of gonorrhoea in adults. Int J STD AIDS 2020;0. doi:10.1177\/0956462420949126","DOI":"10.1177\/0956462420949126"},{"key":"2026080310201422000_dtb.2025.000038v1.4","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac805"},{"key":"2026080310201422000_dtb.2025.000038v1.5","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2020-054653"},{"key":"2026080310201422000_dtb.2025.000038v1.6","doi-asserted-by":"crossref","DOI":"10.1186\/s12887-024-05382-x","article-title":"Epidemiology of ophthalmia neonatorum: a systematic review and meta-analysis","volume":"25","author":"Asiamah","year":"2025","journal-title":"BMC Pediatr"},{"key":"2026080310201422000_dtb.2025.000038v1.7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.oftal.2021.01.013","article-title":"Bacterial eye infections associated with sexual transmission infections: A review","volume":"97","author":"Godoy-Mancilla","year":"2022","journal-title":"Arch Soc Esp Oftalmol (Engl Ed)"},{"key":"2026080310201422000_dtb.2025.000038v1.8","unstructured":"World Health Organization . Multi-drug-resistant gonorrhoea. www.who.int; 2024. Available: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/multi-drug-resistant-gonorrhoea [Accessed 11 Oct 2025]."},{"key":"2026080310201422000_dtb.2025.000038v1.9","unstructured":"GOVUK . Sexually transmitted infections and screening for chlamydia in England: 2024 report. GOV.UK; 2025. Available: https:\/\/www.gov.uk\/government\/statistics\/sexually-transmitted-infections-stis-annual-data-tables\/sexually-transmitted-infections-and-screening-for-chlamydia-in-england-2024-report [Accessed 11 Oct 2025]."},{"key":"2026080310201422000_dtb.2025.000038v1.10","unstructured":"UK Health Security Agency. Notifiable diseases and how to report them. GOV.UK; 2024. Available: https:\/\/www.gov.uk\/guidance\/notifiable-diseases-and-how-to-report-them [Accessed 11 Oct 2025]."},{"key":"2026080310201422000_dtb.2025.000038v1.11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0132776","article-title":"Self-Collected versus Clinician-Collected Sampling for Chlamydia and Gonorrhea Screening: A Systemic Review and Meta-Analysis","volume":"10","author":"Lunny","year":"2015","journal-title":"PLoS One"},{"key":"2026080310201422000_dtb.2025.000038v1.12","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2024-056386"},{"key":"2026080310201422000_dtb.2025.000038v1.13","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1177\/09564624251345195","article-title":"British Association of Sexual Health and HIV UK National Guideline for the Management of infection with Neisseria gonorrhoeae, 2025","volume":"36","author":"Fifer","year":"2025","journal-title":"Int J STD AIDS"},{"key":"2026080310201422000_dtb.2025.000038v1.14","unstructured":"UK Health Security Agency UK Standards for Microbiology Investigations. UK SMI V 37i5: Chlamydia and gonorrhoea infection \u2013 testing by nucleic acid amplification tests (NAATs) [Internet]. London: UKHSA; 2024 Dec [Internet]. UKHSA; 2024. Available: https:\/\/www.rcpath.org\/static\/9173ccae-7d23-4eb9-b8eaf50c05b3889e\/UK-SMI-V-37i5-Chlamydia-and-Gonorrhoea-infection-testing-by-Nucleic-Acid-Amplification-Tests-December-2024.pdf [Accessed 17 May 2026]."},{"key":"2026080310201422000_dtb.2025.000038v1.15","doi-asserted-by":"crossref","unstructured":"Jiang T-T , Cao N-X , Luo W , et al . Performance and acceptability of self-collected specimens for diagnosis of rectal and pharyngeal Chlamydia trachomatis and Neisseria gonorrhoeae infections among men who have sex with men in China: a randomized controlled trial. BMC Infect Dis 2024;24. doi:10.1186\/s12879-024-10273-8","DOI":"10.1186\/s12879-024-10273-8"},{"key":"2026080310201422000_dtb.2025.000038v1.16","unstructured":"World Health Organization . Global health sector strategies [internet]. www.who.int; 2022. Available: https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/6b18ac34-f56a-466e-9660-b5653cb52ef0\/content [Accessed 11 Oct 2025]."},{"key":"2026080310201422000_dtb.2025.000038v1.17","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1093\/cid\/ciaf699","article-title":"Point-of-care Tests for Chlamydia trachomatis and Neisseria gonorrhoeae: Review of the Literature","volume":"82","author":"Manabe","year":"2026","journal-title":"Clin Infect Dis"},{"key":"2026080310201422000_dtb.2025.000038v1.18","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41572-019-0128-6","article-title":"Gonorrhoea","volume":"5","author":"Unemo","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"2026080310201422000_dtb.2025.000038v1.19","doi-asserted-by":"crossref","unstructured":"Griner SB , Garza SR , Alkhatib SA , et al . Point-of-care testing for chlamydia and gonorrhoea: a narrative review of patient perspectives and implementation into non-traditional settings. Sex Transm Infect 2026. doi:10.1136\/sextrans-2025-056736","DOI":"10.1136\/sextrans-2025-056736"},{"key":"2026080310201422000_dtb.2025.000038v1.20","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1093\/jac\/dkaf109","article-title":"The continuing evolution of antibiotic resistance in Neisseria gonorrhoeae: past, present and future threats to effective treatment","volume":"80","author":"Fifer","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"2026080310201422000_dtb.2025.000038v1.21","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7312a2"},{"key":"2026080310201422000_dtb.2025.000038v1.22","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00479-6"},{"key":"2026080310201422000_dtb.2025.000038v1.23","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaf071"},{"key":"2026080310201422000_dtb.2025.000038v1.24","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2022.27.46.2200803","article-title":"Detection of 10 cases of ceftriaxone-resistant Neisseria gonorrhoeae in the United Kingdom, December 2021 to June 2022","volume":"27","author":"Day","year":"2022","journal-title":"Euro Surveill"},{"key":"2026080310201422000_dtb.2025.000038v1.25","doi-asserted-by":"crossref","unstructured":"Ber\u00e7ot B , Cam\u00e9l\u00e9na F , M\u00e9rim\u00e8che M , et al . Ceftriaxone-resistant, multidrug-resistant Neisseria gonorrhoeae with a novel mosaic penA-237.001 gene, France. 2022. Available: https:\/\/doi.org\/10.2807\/1560-7917.ES.2022.27.50.2200899","DOI":"10.2807\/1560-7917.ES.2022.27.50.2200899"},{"key":"2026080310201422000_dtb.2025.000038v1.26","unstructured":"Quarterly report on diagnoses of syphilis, gonorrhoea and ceftriaxone-resistant gonorrhoea in England: provisional data. GOVUK; 2026. Available: https:\/\/www.gov.uk\/government\/publications\/sti-quarterly-surveillance-reports-provisional-data\/quarterly-report-on-diagnoses-of-syphilis-gonorrhoea-and-ceftriaxone-resistant-gonorrhoea-in-england-provisional-data-march-2026 [Accessed 17 May 2026]."},{"key":"2026080310201422000_dtb.2025.000038v1.27","unstructured":"Gonococcal antimicrobial surveillance programme (GASP). Available: https:\/\/www.who.int\/initiatives\/gonococcal-antimicrobial-surveillance-programme [Accessed 17 May 2026]."},{"key":"2026080310201422000_dtb.2025.000038v1.28","unstructured":"UK. GRASP report: data to September 2025. GOVUK; 2025. Available: https:\/\/www.gov.uk\/government\/publications\/gonococcal-resistance-to-antimicrobials-surveillance-programme-grasp-report\/grasp-report-data-to-september-2025 [Accessed 4 Dec 2025]."},{"key":"2026080310201422000_dtb.2025.000038v1.29","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-024-01023-3"},{"key":"2026080310201422000_dtb.2025.000038v1.30","doi-asserted-by":"crossref","first-page":"100737","DOI":"10.1016\/j.lanepe.2023.100737","article-title":"Treatment of bacterial sexually transmitted infections in Europe: gonorrhoea, Mycoplasma genitalium, and syphilis","volume":"34","author":"Mitj\u00e0","year":"2023","journal-title":"The Lancet Regional Health - Europe"},{"key":"2026080310201422000_dtb.2025.000038v1.31","unstructured":"Centers for Disease Control and Prevention . Gonococcal infections among adolescents and adults - STI treatment guidelines [Internet]. www.cdc.gov; 2021. Available: https:\/\/www.cdc.gov\/std\/treatment-guidelines\/gonorrhea-adults.htm [Accessed 17 May 2026]."},{"key":"2026080310201422000_dtb.2025.000038v1.32","unstructured":"Canada Gonorrhea guide: Treatment and follow-up [Internet]. www.canada.ca; 2021. Available: https:\/\/www.canada.ca\/en\/public-health\/services\/infectious-diseases\/sexual-health-sexually-transmitted-infections\/canadian-guidelines\/gonorrhea\/treatment-follow-up.html [Accessed 17 May 2026]."},{"key":"2026080310201422000_dtb.2025.000038v1.33","unstructured":"Updated recommendations for the treatment of Neisseria gonorrhoeae, Chlamydia trachomatis, and Treponema pallidum (syphilis) and new recommendations on syphilis testing and partner services [Internet]. WhoInt World Health Organization; 2024. Available: https:\/\/www.who.int\/publications\/i\/item\/9789240090767 [Accessed 17 May 2026]."},{"key":"2026080310201422000_dtb.2025.000038v1.34","doi-asserted-by":"crossref","first-page":"S231","DOI":"10.1093\/cid\/ciaf607","article-title":"Cefixime for the Treatment of Neisseria gonorrhoeae Infections in a Setting With Increased Antimicrobial Resistance: A Retrospective Study in Hanoi, Vietnam","volume":"81","author":"Adamson","year":"2026","journal-title":"Clinical Infectious Diseases"},{"key":"2026080310201422000_dtb.2025.000038v1.35","unstructured":"MHRA . Fluoroquinolone antibiotics: must now only be prescribed when other commonly recommended antibiotics are inappropriate. GOVUK; 2024. Available: https:\/\/www.gov.uk\/drug-safety-update\/fluoroquinolone-antibiotics-must-now-only-be-prescribed-when-other-commonly-recommended-antibiotics-are-inappropriate [Accessed 4 Dec 2025]."},{"key":"2026080310201422000_dtb.2025.000038v1.36","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1284665","article-title":"Global trends of antimicrobial resistance rates in Neisseria gonorrhoeae: a systematic review and meta-analysis","volume":"15","author":"Hooshiar","year":"2024","journal-title":"Front Pharmacol"},{"key":"2026080310201422000_dtb.2025.000038v1.37","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac371"},{"key":"2026080310201422000_dtb.2025.000038v1.38","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/cid\/ciaa596","article-title":"Resistance-Guided Treatment of Gonorrhea: A Prospective Clinical Study","volume":"73","author":"Klausner","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026080310201422000_dtb.2025.000038v1.39","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2024.2401560"},{"key":"2026080310201422000_dtb.2025.000038v1.40","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-064782","article-title":"Optimisation of treatments for oral Neisseria gonorrhoeae infection: Pharmacokinetics Study (STI-PK project) - study protocol for non-randomised clinical trial","volume":"12","author":"Kong","year":"2022","journal-title":"BMJ Open"},{"key":"2026080310201422000_dtb.2025.000038v1.41","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa300"},{"key":"2026080310201422000_dtb.2025.000038v1.42","unstructured":"Coleman H , Samuel I , Soni S , et al . BASHH summary guidance on testing for sexually transmitted infections. 2023. Available: https:\/\/www.bashh.org\/_userfiles\/pages\/files\/resources\/bashh_summary_guidance_on_stis_testing_2023.pdf [Accessed 4 Dec 2025]."},{"key":"2026080310201422000_dtb.2025.000038v1.43","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0b013e32833a8844"},{"key":"2026080310201422000_dtb.2025.000038v1.44","unstructured":"Saunders J . Writing group Co-chairs Group members Dedication British Association for Sexual Health and HIV\/British HIV Association guidelines on the use of HIV pre-exposure prophylaxis (PrEP) 2025. Available: https:\/\/www.bashh.org\/_userfiles\/pages\/files\/prep_2025.pdf [Accessed 17 May 2026]."},{"key":"2026080310201422000_dtb.2025.000038v1.45","unstructured":"O\u2019Byrne P , Orser L . Should we still treat asymptomatic Neisseria gonorrhoeae and Chlamydia trachomatis contacts in the era of NAATs? Reviewing data from the GetaKit study to inform practice. Sexually Transmitted Infections. Sexually Transmitted Infections; 2025. Available: https:\/\/sti.bmj.com\/content\/early\/2025\/10\/15\/sextrans-2025-056697.abstract [Accessed 17 May 2026]."},{"key":"2026080310201422000_dtb.2025.000038v1.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.03.111"},{"key":"2026080310201422000_dtb.2025.000038v1.47","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-021-00388-3","article-title":"Looking beyond meningococcal B with the 4CMenB vaccine: the Neisseria effect","volume":"6","author":"Ruiz Garc\u00eda","year":"2021","journal-title":"NPJ Vaccines"},{"key":"2026080310201422000_dtb.2025.000038v1.48","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiae383"},{"key":"2026080310201422000_dtb.2025.000038v1.49","doi-asserted-by":"crossref","unstructured":"Wang B , Giles L , Andraweera P , et al . Long-term 4CMenB Vaccine Effectiveness Against Gonococcal Infection at Four Years Post-Program Implementation: Observational Case-Control Study. Open Forum Infect Dis 2025;12. doi:10.1093\/ofid\/ofae726","DOI":"10.1093\/ofid\/ofae726"},{"key":"2026080310201422000_dtb.2025.000038v1.50","unstructured":"UK . 4CMenB vaccine for prevention of gonorrhoea: information for healthcare practitioners. GOVUK; 2025. Available: https:\/\/www.gov.uk\/government\/publications\/4cmenb-vaccine-for-gonorrhoea-information-for-healthcare-practitioners\/4cmenb-vaccine-for-prevention-of-gonorrhoea-information-for-healthcare-practitioners [Accessed 4 Dec 2025]."},{"key":"2026080310201422000_dtb.2025.000038v1.51","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S1473-3099(21)00744-1","article-title":"Public health impact and cost-effectiveness of gonorrhoea vaccination: an integrated transmission-dynamic health-economic modelling analysis","volume":"22","author":"Whittles","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2026080310201422000_dtb.2025.000038v1.52","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00236-6"},{"key":"2026080310201422000_dtb.2025.000038v1.53","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(26)00126-X"}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2025.000038","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T17:20:29Z","timestamp":1785777629000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2025.000038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":53,"alternative-id":["10.1136\/dtb.2025.000038"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2025.000038","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"value":"0012-6543","type":"print"},{"value":"1755-5248","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]}}}